E-cigarettes are less harmful than smoking
Nutt, David J.; Phillips, Lawrence D.; Balfour, David; Curran, H. Valerie; Dockrell, Martin; Foulds, Jonathan

Published in:
Lancet

DOI:
10.1016/S0140-6736(15)00253-6

Publication date:
2016

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-cigarettes are indeed less harmful than smoking

Your Editorial\(^1\) criticising Public Health England’s review of electronic cigarettes focuses on three supposed short-comings of the paper by Nutt et al\(^2\): (1) lack of evidence, (2) reliance on the opinions of participants, and (3) potential bias arising from the selection of participants and conflicts of interest by some of the experts. As authors of the original paper, we find these three criticisms have over-generalised the evidence issue, failed to respect the knowledge and experience of the experts, and did not take into account the many measures to minimize potential bias.

First, the lack of evidence. That criticism does not apply to smoked cigarettes and e-cigarettes. There is abundant evidence about the harm of cigarettes. The paucity of evidence for serious harm to users of e-cigarettes over the years since they were first marketed in 2006, with millions purchased, is itself evidence. In addition, biomarkers of potential future harm are broadly reassuring\(^3-5\).

Second, reliance on the opinions of the participants. The approach we used in the study, decision conferencing\(^6\), sought from participants their expert judgements, not opinions. The criteria and their definitions were taken from three drug harm studies, the ACMD’s original formulation\(^7\), the 2010 study of UK drug harms published in the Lancet\(^8\), and the 2013 replication for EU drug harms\(^9\). Judgements about scores were based on data along with our knowledge and experience of the degree of harm, and plausible causal mechanisms for the harm. When data were available, they were discussed openly by the group for their validity and reliability. When data were sparse or lacking, we relied on logical inferences (e.g., the dearth of evidence of dying directly from an overdose of smoking led us to infer that cigarettes are not very harmful on that criterion, so we gave it a low score, but we assigned e-cigarettes a higher harm score for that effect because the nicotine solution in the cartridges could potentially be directly accessed). A strength of the multi-criteria decision analysis (MCDA) model\(^10\) is that it incorporates both the data and judgements about the relevance of the data, thus capturing meaningful differences in the relative importance of the effects.

Third, bias in the experts. We selected participants who are recognised as experts by their publications, experience and generally-acknowledged professional standing, bringing diverse perspectives and expertise that could be relevant to assessing the harm from nicotine products. We included experts in behavioural pharmacology, legal aspects of tobacco control, smoking policy, toxicology, neuro-psychopharmacology, psychopharmacology, public health sciences and internal medicine, who collectively have published over 300 scientific publications relevant to understanding nicotine and tobacco harm. It was misleading of the Lancet to characterise the authors as having “no prespecified expertise in tobacco control” as the project was about relative harms of nicotine products not tobacco policy.

As for conflicts of interest, the decision conference process is designed to ensure that participants of different persuasions challenge each other, and the facilitator asks participants giving judgements to support them with studies, data or experience. The facilitator ensured that peer review operated on-the-spot as the MCDA model was created in a step-by-step, structured process\(^10\). Consistency
checks and sensitivity of overall results to the input scores and weights were thoroughly explored, with model results found to be very robust to imprecision in the data and the few disagreements among the experts. These procedures made it impossible for a single participant with a potential bias to have any meaningful influence on the process outcome.

Potential sources of conflict of interest were disclosed at the meeting, and those in the prior three years were disclosed in the published paper. We were informed by EuroSwiss Health that they have no funding from any tobacco or e-cigarette company; this was a requirement for accepting their funding. Funds provided were not from tobacco or e-cigarette companies, and as stated in the paper, EuroSwiss Health and Lega Italiana Anti Fumo (LIAF) had no influence on the MCDA process.

We are confident that the nicotine products study applied an appropriate structured process with a requisite diversity of experts who engaged in constructive discourse in building a model that represented the most scientifically sound assessment of the relative harms of nicotine products. Our model’s results for harms to the user provided Public Health England with the basis for their correct calculation of the estimate that e-cigarettes are 95% less harmful to the user than smoking. Or, as we prefer, smoking is estimated to be 20 times more harmful to the user than vaping.

(745 words)

References

David J Nutt1, Lawrence D Phillips2, David Balfour3, H. Valerie Curran4, Martin Dockrell5, Jonathan Foulds6, Karl Fagerstrom7, Kgosi Letlape8, Riccardo Polosa9, John Ramsey10, David Sweanor11

1. Edmond J Safra Professor of Neuropsychopharmacology, Imperial College London UK
2. Emeritus Professor of Decision Sciences, Department of Management, London School of Economics & Political Science, and Director of Facilitations Ltd UK
3. Emeritus Professor of Behavioural Pharmacology, University of Dundee UK
4. Professor of Psychopharmacology, University College London UK
5. Director of Policy and Research, ASH UK
6. Professor, Public Health Sciences, College of Medicine, Penn State University USA
7. Fagerström Consulting Sweden
8. Past President, World Medical Association S Africa
9. Director for the Centre for the Prevention and Cure of Tobacco Use, University of Catania Italy
10. Analytical toxicologist and Director of TICTAC Communications Ltd. at St. George’s, University of London UK
11. Adjunct Professor, Faculty of Law, and Centre for Health Law, Policy and Ethics, University of Ottawa

The 12th author, Anders Milton, was not available for a reply.